Cited 0 times in
Patient-reported outcomes (PROs) from DESTINY-Breast04, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs treatment of physician's choice (TPC) in patients (pts) with HER2-low metastatic breast cancer (MBC)
DC Field | Value | Language |
---|---|---|
dc.date.accessioned | 2023-06-02T01:04:59Z | - |
dc.date.available | 2023-06-02T01:04:59Z | - |
dc.date.issued | 2022-09 | - |
dc.identifier.issn | 0923-7534 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/194636 | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Oxford University Press | - |
dc.relation.isPartOf | ANNALS OF ONCOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Patient-reported outcomes (PROs) from DESTINY-Breast04, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs treatment of physician's choice (TPC) in patients (pts) with HER2-low metastatic breast cancer (MBC) | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Others | - |
dc.contributor.googleauthor | N.T. Ueno | - |
dc.contributor.googleauthor | W. Jacot | - |
dc.contributor.googleauthor | T. Yamashita | - |
dc.contributor.googleauthor | J. Sohn | - |
dc.contributor.googleauthor | E. Tokunaga | - |
dc.contributor.googleauthor | A. Prat | - |
dc.contributor.googleauthor | J. Tsurutani | - |
dc.contributor.googleauthor | Y.H. Park | - |
dc.contributor.googleauthor | H.S. Rugo | - |
dc.contributor.googleauthor | B. Xu | - |
dc.contributor.googleauthor | F. Cardoso | - |
dc.contributor.googleauthor | Z. Mitri | - |
dc.contributor.googleauthor | R. Mahtani | - |
dc.contributor.googleauthor | K. Dunton | - |
dc.contributor.googleauthor | Y. Wang | - |
dc.contributor.googleauthor | D. Gambhire | - |
dc.contributor.googleauthor | F. Cottone | - |
dc.contributor.googleauthor | N. Harbeck | - |
dc.contributor.googleauthor | D.A. Cameron | - |
dc.contributor.googleauthor | S. Modi | - |
dc.identifier.doi | 10.1016/j.annonc.2022.07.256 | - |
dc.relation.journalcode | J00171 | - |
dc.identifier.eissn | 1569-8041 | - |
dc.identifier.url | https://www.sciencedirect.com/science/article/pii/S092375342202107 | - |
dc.citation.volume | 33 | - |
dc.citation.number | Supplement 7 | - |
dc.citation.startPage | S632 | - |
dc.citation.endPage | S633 | - |
dc.identifier.bibliographicCitation | ANNALS OF ONCOLOGY, Vol.33(Supplement 7) : S632-S633, 2022-09 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.